CSIMarket Company Name, Ticker, Suppliers, else..
 
Aeon Biopharma inc   (NYSEAMER: AEON)
 
Price: $0.3544 $0.06 22.207%
Day's High: $0.36399999260902405 Week Perf: 47.05 %
Day's Low: $ 0.29 30 Day Perf: 28.87 %
Volume (M): 10,638,710 52 Wk High: $ 1.45
Volume (M$): $ 0 52 Wk Avg: $0.82
Open: $0.30 52 Wk Low: $0.18



 Market Capitalization (Millions $) 18
 Shares Outstanding (Millions) 51
 Employees 8
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -55
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aeon Biopharma Inc is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for various diseases. They focus on advancing the treatment options available to patients and improving their quality of life. Aeon Biopharma Inc conducts research, clinical trials, and manufacturing of its pharmaceutical products. They strive to bring new and effective treatments to the market by leveraging cutting-edge technologies and collaborations with industry experts. Their mission is to address unmet medical needs and make a positive impact on the health and well-being of patients worldwide.


   Company Address: 5 Park Plaza Irvine 92614 CA
   Company Phone Number: 354-6499   Stock Exchange / Ticker: NYSEAMER AEON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD        0.13% 
ALKS   -1.87%    
BMRN   -1.26%    
RPRX   -8.11%    
VRTX   -8.07%    
VTRS   -2.95%    
• View Complete Report
   



Product Service News

AEON Biopharmas Strategic Move Towards Financial Resilience A New Chapter in Compliance and Growth

Published Fri, Apr 25 2025 8:51 PM UTC

In a noteworthy development, AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical enterprise focusing on the innovative use of botulinum toxin complexes for various therapeutic treatments, announced a pivotal step towards ensuring the continuity of its NYSE American listing. The company triumphantly disclosed receiving an acceptance letter from NYSE American...
Shares

AEON Biopharma Faces NYSE Compliance Challenges Amid Strategic Moves and Ongoing Financial Struggles

Published Fri, Feb 7 2025 9:05 PM UTC

AEON Biopharma Faces NYSE Compliance Challenges Amid Strategic Moves and Ongoing Financial StrugglesIRVINE, Calif. In a recent development that has raised concerns among investors, AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical entity specializing in the development of a botulinum toxin complex via the 351(k) biosimilar pathway, received a notice on ...
Shares

AEON Biopharma Navigates Regulatory Gains and Clinical Trials as It Launches Public Offering,

Published Sat, Jan 4 2025 1:02 AM UTC

AEON Biopharma, Inc. Launches Proposed Public Offering Amid FDA Progress and Market Challenges IRVINE, Calif. Jan. 03, 2025 AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company dedicated to advancing a botulinum toxin complex through the 351(k) biosimilar pathway, has officially announced the commencement of a public offering. This strategic move...
Stocks on the Move

AEON Biopharmas Focus Realigns Towards Biosimilar Pathway for ABP-450 A Shift in Strategy

Published Wed, Jul 17 2024 9:14 PM UTC

In recent news, AEON Biopharma, a prominent pharmaceutical company, announced a strategic reprioritization to pursue a biosimilar pathway for ABP-450. This shift in focus has come after the preliminary results of AEON Biopharma s Phase 2 trial for chronic migraine treatment failed to show significant improvement over a placebo. At the same time, AEON Biopharma s shares have...
Stocks on the Move

Analyzing the Recent Sell-off in Aeon Biopharma Inc Shares Factors Impacting Performance

Published Tue, Jul 16 2024 9:39 AM UTC

Aeon Biopharma Inc, a clinical-stage biopharmaceutical company focused on the development of a botulinum toxin complex for multiple therapeutic indications, has experienced a significant sell-off in its shares recently. This article aims to explore the underlying factors behind this decline, particularly by examining recent events and financial performance.Event 1: Sunshine ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.47
Working Capital Ratio 0.54
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.44 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.07 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -6,827,875
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.